RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Regulatory Update

Regulatory Update

Posted 01 September 2010 | By

In its efforts to improve over-the-counter (OTC) drug labels, the US Food and Drug Administration (FDA) announced the availability of new industry guidelines for designing, conducting and analyzing label comprehension studies. Often required before an OTC medication is approved-or following a change in formula or indications-these qualitative studies are conducted to assess the extent to which patients are able to understand and apply information from OTC drug labels. Products that fail to adequately communicate this information can cause patient errors that lead to serious adverse reactions.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.